{"symbol":"DEE75","id":"41776","medgen_id":"C5193099","alternate_symbols":["EIEE75"],"alternate_names":["EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 75"],"type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032752\"}","{\"db\":\"OMIM\",\"id\":\"618437\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618437\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 75\"}","{\"db\":\"OMIM\",\"id\":\"618437\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE75\"}","{\"db\":\"OMIM\",\"id\":\"612036.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612036.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612036.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612036.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612036.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612036.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612036.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618437\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618437\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 75"}
{"symbol":"VMLDS1","id":"872","medgen_id":"C4551950","alternate_symbols":[],"alternate_names":["Van Maldergem syndrome 1 (VMLDS1)"],"type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011070\"}","{\"db\":\"OMIM\",\"id\":\"601390\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"314679\"}","{\"db\":\"OMIM\",\"id\":\"603057.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603057.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603057.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601390\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Van Maldergem syndrome 1"}
{"symbol":"NEDMIGS","id":"35845","medgen_id":"C4310745","alternate_symbols":["MRT55"],"alternate_names":["NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY AND GRAY SCLERAE"],"type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014886\"}","{\"db\":\"OMIM\",\"id\":\"617051\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"488627\"}","{\"db\":\"OMIM\",\"id\":\"616283.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY AND GRAY SCLERAE\"}","{\"db\":\"OMIM\",\"id\":\"616283.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY AND GRAY SCLERAE\"}","{\"db\":\"OMIM\",\"id\":\"617051\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY AND GRAY SCLERAE\"}","{\"db\":\"OMIM\",\"id\":\"617051\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MRT55\"}","{\"db\":\"OMIM\",\"id\":\"617051\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Mental retardation, autosomal recessive 55"}
{"symbol":"DEE76","id":"42118","medgen_id":"C5193113","alternate_symbols":["DECAM","EIEE76"],"alternate_names":["DEVELOPMENTAL DELAY, EPILEPTIC ENCEPHALOPATHY, CEREBRAL ATROPHY, AND ABNORMAL MYELINATION","EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 76"],"type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032768\"}","{\"db\":\"OMIM\",\"id\":\"618468\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618468\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL DELAY, EPILEPTIC ENCEPHALOPATHY, CEREBRAL ATROPHY, AND ABNORMAL MYELINATION\"}","{\"db\":\"OMIM\",\"id\":\"612458.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 76\"}","{\"db\":\"OMIM\",\"id\":\"612458.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 76\"}","{\"db\":\"OMIM\",\"id\":\"612458.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 76\"}","{\"db\":\"OMIM\",\"id\":\"612458.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 76\"}","{\"db\":\"OMIM\",\"id\":\"612458.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 76\"}","{\"db\":\"OMIM\",\"id\":\"612458.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 76\"}","{\"db\":\"OMIM\",\"id\":\"612458.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 76\"}","{\"db\":\"OMIM\",\"id\":\"612458.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 76\"}","{\"db\":\"OMIM\",\"id\":\"618468\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 76\"}","{\"db\":\"OMIM\",\"id\":\"618468\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DECAM\"}","{\"db\":\"OMIM\",\"id\":\"618468\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE76\"}","{\"db\":\"OMIM\",\"id\":\"618468\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618468\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 76"}
{"symbol":"DEE79","id":"42881","medgen_id":"C5231410","alternate_symbols":["EIEE79"],"alternate_names":["EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 79"],"type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032813\"}","{\"db\":\"OMIM\",\"id\":\"618559\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618559\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 79\"}","{\"db\":\"OMIM\",\"id\":\"618559\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE79\"}","{\"db\":\"OMIM\",\"id\":\"137142.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"137142.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"137142.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618559\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618559\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 79"}
{"symbol":"COXPD7","id":"9599","medgen_id":"C3150801","alternate_symbols":[],"alternate_names":[],"type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013306\"}","{\"db\":\"OMIM\",\"id\":\"613559\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"254930\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Combined+oxidative+phosphorylation+deficiency+7/8019\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613559\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Combined oxidative phosphorylation deficiency 7"}
{"symbol":"DEE72","id":"41566","medgen_id":"C5193063","alternate_symbols":["EIEE72"],"alternate_names":["EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 72"],"type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032710\"}","{\"db\":\"OMIM\",\"id\":\"618374\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618374\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 72\"}","{\"db\":\"OMIM\",\"id\":\"618374\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE72\"}","{\"db\":\"OMIM\",\"id\":\"601725.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601725.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618374\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618374\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 72"}
{"id":"10380","medgen_id":"C2936833","alternate_symbols":[],"alternate_names":[],"type":"Disease","keywords":[],"attribute_content":[],"xrefs":[],"name":"Mycobacterium tuberculosis, susceptibility to infection by"}
{"symbol":"DEE71","id":"41411","medgen_id":"C5193030","alternate_symbols":["EIEE71"],"alternate_names":["EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 71","GLUTAMINASE DEFICIENCY WITH NEONATAL EPILEPTIC ENCEPHALOPATHY"],"type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032678\"}","{\"db\":\"OMIM\",\"id\":\"618328\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618328\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 71\"}","{\"db\":\"OMIM\",\"id\":\"618328\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GLUTAMINASE DEFICIENCY WITH NEONATAL EPILEPTIC ENCEPHALOPATHY\"}","{\"db\":\"OMIM\",\"id\":\"618328\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE71\"}","{\"db\":\"OMIM\",\"id\":\"138280.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"138280.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"138280.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618328\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618328\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 71"}
{"symbol":"KILQS","id":"41330","medgen_id":"CN293532","alternate_symbols":[],"alternate_names":[],"type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"619080\",\"type\":\"MIM\"}","{\"db\":\"Undiagnosed Diseases Network,NIH\",\"id\":\"18c3fb5f-b11b-44db-a639-\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"619080\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Kilquist syndrome"}
{"id":"41569","medgen_id":"C5193065","alternate_symbols":["DEE73","EIEE73"],"alternate_names":["DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 73","EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 73"],"type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0034106\"}","{\"db\":\"OMIM\",\"id\":\"618379\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"544503\"}","{\"db\":\"OMIM\",\"id\":\"609247.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 73\"}","{\"db\":\"OMIM\",\"id\":\"609247.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 73\"}","{\"db\":\"OMIM\",\"id\":\"618379\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 73\"}","{\"db\":\"OMIM\",\"id\":\"618379\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 73\"}","{\"db\":\"OMIM\",\"id\":\"618379\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DEE73\"}","{\"db\":\"OMIM\",\"id\":\"618379\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE73\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0034106\",\"ref_field\":\"name\"}"],"name":"Rnf13-related severe early-onset epileptic encephalopathy"}
{"id":"6926","medgen_id":"C2751321","alternate_symbols":[],"alternate_names":["MACS SYNDROME","TALL FOREHEAD, SPARSE HAIR, SKIN HYPEREXTENSIBILITY, AND SCOLIOSIS"],"type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013115\"}","{\"db\":\"OMIM\",\"id\":\"613075\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"217335\"}","{\"db\":\"OMIM\",\"id\":\"610222.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MACS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"610222.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MACS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"610222.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MACS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"610222.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MACS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"613075\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MACS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"613075\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TALL FOREHEAD, SPARSE HAIR, SKIN HYPEREXTENSIBILITY, AND SCOLIOSIS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Macrocephaly%2C+alopecia%2C+cutis+laxa%2C+and+scoliosis/8773\",\"ref_field\":\"name\"}"],"name":"Macrocephaly, alopecia, cutis laxa, and scoliosis"}
{"id":"23402","medgen_id":"C0023903","alternate_symbols":[],"alternate_names":["Liver tumor"],"type":"Finding","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002896\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0004721\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002896\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Liver tumor\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002896\",\"ref_field\":\"name\"}"],"name":"Neoplasm of the liver"}
{"id":"22335","medgen_id":"C1849943","alternate_symbols":[],"alternate_names":["Cranial suture synostosis","Craniostenosis","Craniosyostosis","Deformity of the skull","Early fusion of cranial sutures","Premature closure of cranial sutures","Premature fontanel closure","Premature suture closure"],"type":"Finding","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001365\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004494\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005448\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005457\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005467\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008492\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0015469\"}","{\"db\":\"OMIM\",\"id\":\"PS123100\",\"type\":\"Phenotypic series\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cranial suture synostosis\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Craniostenosis\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Craniosyostosis\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Deformity of the skull\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Early fusion of cranial sutures\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Premature closure of cranial sutures\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Premature fontanel closure\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Premature suture closure\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001363\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"PS123100\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}"],"name":"Craniosynostosis"}
{"id":"17294","medgen_id":"C0022665","alternate_symbols":[],"alternate_names":["Neoplasia of the kidneys","Renal neoplasia","Renal tumors"],"type":"Finding","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005933\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009726\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0021163\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009726\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Neoplasia of the kidneys\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009726\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Renal neoplasia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009726\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Renal tumors\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009726\",\"ref_field\":\"name\"}"],"name":"Renal neoplasm"}
{"symbol":"DEE74","id":"41594","medgen_id":"C5193074","alternate_symbols":["EIEE74"],"alternate_names":["EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 74"],"type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032725\"}","{\"db\":\"OMIM\",\"id\":\"618396\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618396\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 74\"}","{\"db\":\"OMIM\",\"id\":\"618396\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE74\"}","{\"db\":\"OMIM\",\"id\":\"137164.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"137164.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"137164.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618396\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618396\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 74"}
{"symbol":"CRS1","id":"1196","medgen_id":"C4551902","alternate_symbols":["CRS","CSO"],"alternate_names":[],"type":"Disease","mode_of_inheritance":"Heterogenous inheritance pattern","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007399\"}","{\"db\":\"OMIM\",\"id\":\"123100\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"63440\"}","{\"db\":\"OMIM\",\"id\":\"123100\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CRS\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000225047\",\"ref_field\":\"mode_of_inheritance\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Craniosynostosis+1/8111\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"123100\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Craniosynostosis 1"}
{"symbol":"DEE78","id":"42883","medgen_id":"C5231409","alternate_symbols":["EIEE78"],"alternate_names":["EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 78"],"type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032812\"}","{\"db\":\"OMIM\",\"id\":\"618557\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618557\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 78\"}","{\"db\":\"OMIM\",\"id\":\"618557\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE78\"}","{\"db\":\"OMIM\",\"id\":\"137140.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"137140.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"137140.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"137140.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"137140.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618557\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618557\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 78"}
{"symbol":"DEE70","id":"41329","medgen_id":"C4749023","alternate_symbols":["EIEE70"],"alternate_names":["EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 70"],"type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032663\"}","{\"db\":\"OMIM\",\"id\":\"618298\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618298\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 70\"}","{\"db\":\"OMIM\",\"id\":\"618298\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE70\"}","{\"db\":\"OMIM\",\"id\":\"608723.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"608723.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"608723.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618298\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618298\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 70"}
{"public_definition":"Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.","symbol":"PGL1","id":"5731","medgen_id":"C1868633","alternate_symbols":["CBT1","PGL"],"alternate_names":["Glomus tumor","Glomus tumors familial 1","PARAGANGLIOMA, CAROTID BODY","PARAGANGLIOMAS, FAMILIAL NONCHROMAFFIN, 1","PGL 1","Paraganglioma - glomus jugulare","Paragangliomas familial 1","Paragangliomata"],"content":"{\"Citation\":[{\"@Type\":\"review\",\"ID\":{\"$\":\"20816580\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301715\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1548\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ASCO, 2010\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"20065170\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO, 2009\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"2668639\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ES, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24893135\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NANETS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3419007\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG/NSGC, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25394175\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"KCRNC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24319509\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008192\"}","{\"db\":\"OMIM\",\"id\":\"168000\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"29072\"}","{\"db\":\"OMIM\",\"id\":\"168000\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARAGANGLIOMA, CAROTID BODY\"}","{\"db\":\"OMIM\",\"id\":\"168000\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARAGANGLIOMAS, FAMILIAL NONCHROMAFFIN, 1\"}","{\"db\":\"OMIM\",\"id\":\"168000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CBT1\"}","{\"db\":\"OMIM\",\"id\":\"168000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PGL\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Paragangliomas+1/5578\",\"ref_field\":\"name\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008192\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1548\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"168000\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Paragangliomas 1"}
{"public_definition":"Mucopolysaccharidosis type II (MPS II; also known as Hunter syndrome) is an X-linked multisystem disorder characterized by glycosaminoglycan (GAG) accumulation. The vast majority of affected individuals are male; on rare occasion heterozygous females manifest findings. Age of onset, disease severity, and rate of progression vary significantly among affected males. In those with early progressive disease, CNS involvement (manifest primarily by progressive cognitive deterioration), progressive airway disease, and cardiac disease usually result in death in the first or second decade of life. In those with slowly progressive disease, the CNS is not (or is minimally) affected, although the effect of GAG accumulation on other organ systems may be early progressive to the same degree as in those who have progressive cognitive decline. Survival into the early adult years with normal intelligence is common in the slowly progressing form of the disease. Additional findings in both forms of MPS II include: short stature; macrocephaly with or without communicating hydrocephalus; macroglossia; hoarse voice; conductive and sensorineural hearing loss; hepatosplenomegaly; dysostosis multiplex; spinal stenosis; and carpal tunnel syndrome.","symbol":"MPS2","id":"10834","medgen_id":"C0026705","alternate_symbols":[],"alternate_names":["Attenuated MPS (subtype; formerly known as mild MPS II)","Hunter Syndrome","I2S deficiency","IDS deficiency","Iduronate 2-sulfatase deficiency","MPS 2","MPS II","SIDS deficiency","Severe MPS II","Sulfoiduronate sulfatase deficiency"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301451\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1274\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21863056\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Giugliani et al., 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25071396\",\"@Source\":\"PubMed\"}}]}","type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010674\"}","{\"db\":\"OMIM\",\"id\":\"309900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"580\"}","{\"db\":\"OMIM\",\"id\":\"309900\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MPS II\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Mucopolysaccharidosis+type+II/4913\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"70737009\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1274\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"309900\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Mucopolysaccharidosis, MPS-II"}
{"public_definition":"Amyotrophic lateral sclerosis (ALS) is a progressive disease that affects motor neurons, which are specialized nerve cells that control muscle movement. These nerve cells are found in the spinal cord and the brain. In ALS, motor neurons die (atrophy) over time, leading to muscle weakness, a loss of muscle mass, and an inability to control movement.There are many different types of ALS; these types are distinguished by their signs and symptoms and their genetic cause or lack of clear genetic association. Most people with ALS have a form of the condition that is described as sporadic, which means it occurs in people with no apparent history of the disorder in their family. People with sporadic ALS usually first develop features of the condition in their late fifties or early sixties. A small proportion of people with ALS, estimated at 5 to 10 percent, have a family history of ALS or a related condition called frontotemporal dementia (FTD), which is a progressive brain disorder that affects personality, behavior, and language. The signs and symptoms of familial ALS typically first appear in one's late forties or early fifties. Rarely, people with familial ALS develop symptoms in childhood or their teenage years. These individuals have a rare form of the disorder known as juvenile ALS.The first signs and symptoms of ALS may be so subtle that they are overlooked. The earliest symptoms include muscle twitching, cramping, stiffness, or weakness. Affected individuals may develop slurred speech (dysarthria) and, later, difficulty chewing or swallowing (dysphagia). Many people with ALS experience malnutrition because of reduced food intake due to dysphagia and an increase in their body's energy demands (metabolism) due to prolonged illness. Muscles become weaker as the disease progresses, and arms and legs begin to look thinner as muscle tissue atrophies. Individuals with ALS eventually lose muscle strength and the ability to walk. Affected individuals eventually become wheelchair-dependent and increasingly require help with personal care and other activities of daily living. Over time, muscle weakness causes affected individuals to lose the use of their hands and arms. Breathing becomes difficult because the muscles of the respiratory system weaken. Most people with ALS die from respiratory failure within 2 to 10 years after the signs and symptoms of ALS first appear; however, disease progression varies widely among affected individuals.Approximately 20 percent of individuals with ALS also develop FTD. Changes in personality and behavior may make it difficult for affected individuals to interact with others in a socially appropriate manner. Communication skills worsen as the disease progresses. It is unclear how the development of ALS and FTD are related. Individuals who develop both conditions are diagnosed as having ALS-FTD.A rare form of ALS that often runs in families is known as ALS-parkinsonism-dementia complex (ALS-PDC). This disorder is characterized by the signs and symptoms of ALS, in addition to a pattern of movement abnormalities known as parkinsonism, and a progressive loss of intellectual function (dementia). Signs of parkinsonism include unusually slow movements (bradykinesia), stiffness, and tremors. Affected members of the same family can have different combinations of signs and symptoms.","symbol":"ALS8","id":"4575","medgen_id":"C1837728","alternate_symbols":[],"alternate_names":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301623\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1450\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"Orphanet, 2007\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Orphanet, Amyotrophic lateral sclerosis, 2007\"},\"URL\":{\"$\":\"https://www.orpha.net/data/patho/Pro/en/Emergency_AmyotrophicLateralSclerosis.pdf\"}}]}","type":"Disease","gard_id":"10499","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012077\"}","{\"db\":\"OMIM\",\"id\":\"608627\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"803\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10499\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Amyotrophic+Lateral+Sclerosis+Type+8/410\",\"ref_field\":\"name\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0012077\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"amyotrophic-lateral-sclerosis\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"608627\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Amyotrophic lateral sclerosis type 8"}
{"public_definition":"GJB1 disorders are typically characterized by peripheral motor and sensory neuropathy with or without fixed CNS abnormalities and/or acute, self-limited episodes of transient neurologic dysfunction (especially weakness and dysarthria). Peripheral neuropathy typically manifests in affected males between ages five and 25 years. Although both men and women are affected, manifestations tend to be less severe in women, some of whom may remain asymptomatic. Less commonly, initial manifestations in some affected individuals are stroke-like episodes (acute fulminant episodes of reversible CNS dysfunction).","symbol":"CMTX1","id":"787","medgen_id":"C0393808","alternate_symbols":["CMT2"],"alternate_names":["CHARCOT-MARIE-TOOTH NEUROPATHY, X-LINKED, 1","CMTX 1","Charcot-Marie-Tooth disease X-linked 1","Charcot-Marie-Tooth peroneal muscular atrophy, X-linked"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301548\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1374\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"2987431\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301532\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1358\",\"@Source\":\"BookShelf\"}]}]}","type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010549\"}","{\"db\":\"OMIM\",\"id\":\"302800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101075\"}","{\"db\":\"OMIM\",\"id\":\"302800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH NEUROPATHY, X-LINKED, 1\"}","{\"db\":\"OMIM\",\"id\":\"302800\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT2\"}","{\"db\":\"NCI\",\"id\":\" C129068\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1374\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"302800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Charcot-Marie-Tooth Neuropathy X Type 1"}
{"symbol":"PCH1A","id":"4003","medgen_id":"CN032785","alternate_symbols":["MRT32","PCH1"],"alternate_names":["Pontocerebellar hypoplasia with anterior horn cell disease","Pontocerebellar hypoplasia with infantile spinal muscular atrophy"],"content":"{\"Citation\":{\"@Abbrev\":\"Int'l SCC for SMA, 2007\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"17761659\",\"@Source\":\"PubMed\"}}}","type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"Gene\",\"id\":\"100852400\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011866\"}","{\"db\":\"OMIM\",\"id\":\"607596\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2254\"}","{\"db\":\"Orphanet\",\"id\":\"88616\"}","{\"db\":\"OMIM\",\"id\":\"614339\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MRT32\"}","{\"db\":\"OMIM\",\"id\":\"607596\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PCH1\"}","{\"db\":\"OMIM\",\"id\":\"607596\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Pontocerebellar hypoplasia type 1A"}
{"public_definition":"GARS1-associated axonal neuropathy (Charcot-Marie-Tooth neuropathy type 2D / distal spinal muscular atrophy V [CMT2D/dSMA-V]) is characterized by adolescent or early-adult onset of weakness in the hands that may be preceded by transient cramping and pain in the hands on exposure to cold and cramping in calf muscles on exertion. This is followed by progressive weakness and atrophy of thenar and first dorsal interosseus muscles; hypothenar eminence is spared until later in the course of illness. The lower limbs are involved in about half of affected individuals, with severity varying from weakness and atrophy of the extensor digitorum brevis and weakness of toe dorsiflexors to classic peroneal muscular atrophy with foot drop. The phenotype is considered the CMT2D subtype when sensory deficits (reduction of pinprick, temperature, touch, and vibration perception in a stocking and [less often] glove pattern) are present and dSMA-V when sensory deficits are absent.","symbol":"HMN5","id":"3091","medgen_id":"C1833308","alternate_symbols":["DHMN5A","DSMAV","DSMAVA","HMN5A"],"alternate_names":["DHMN VA","Distal Spinal Muscular Atrophy V","HMN VA","NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE V","NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA","NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE VA","SPINAL MUSCULAR ATROPHY, DISTAL, TYPE VA"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301420\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1242\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301484\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1307\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301532\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1358\",\"@Source\":\"BookShelf\"}]}]}","type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0015353\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"139536\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DHMN VA\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HMN VA\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE V\"}","{\"db\":\"OMIM\",\"id\":\"600287.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA\"}","{\"db\":\"OMIM\",\"id\":\"600287.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA\"}","{\"db\":\"OMIM\",\"id\":\"600287.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA\"}","{\"db\":\"OMIM\",\"id\":\"600287.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA\"}","{\"db\":\"OMIM\",\"id\":\"600287.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE VA\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINAL MUSCULAR ATROPHY, DISTAL, TYPE VA\"}","{\"db\":\"OMIM\",\"id\":\"606158.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINAL MUSCULAR ATROPHY, DISTAL, TYPE VA\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DHMN5A\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DSMAV\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DSMAVA\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMN5A\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Distal+hereditary+motor+neuronopathy+type+5/8273\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1242\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Distal hereditary motor neuronopathy type 5"}
{"public_definition":"Holt-Oram syndrome (HOS) is characterized by upper-limb defects, congenital heart malformation, and cardiac conduction disease. Upper-limb malformations may be unilateral, bilateral/symmetric, or bilateral/asymmetric and can range from triphalangeal or absent thumb(s) to phocomelia. Other upper-limb malformations can include unequal arm length caused by aplasia or hypoplasia of the radius, fusion or anomalous development of the carpal and thenar bones, abnormal forearm pronation and supination, abnormal opposition of the thumb, sloping shoulders, and restriction of shoulder joint movement. An abnormal carpal bone is present in all affected individuals and may be the only evidence of disease. A congenital heart malformation is present in 75% of individuals with HOS and most commonly involves the septum. Atrial septal defect and ventricular septal defect can vary in number, size, and location. Complex congenital heart malformations can also occur in individuals with HOS. Individuals with HOS with or without a congenital heart malformation are at risk for cardiac conduction disease. While individuals may present at birth with sinus bradycardia and first-degree atrioventricular (AV) block, AV block can progress unpredictably to a higher grade including complete heart block with and without atrial fibrillation.","symbol":"HOS","id":"2051","medgen_id":"C0265264","alternate_symbols":["HOS1"],"alternate_names":["Atrio digital syndrome","Atriodigital dysplasia","Cardiac-limb syndrome","HOS 1","Heart-hand syndrome","Heart-hand syndrome, type 1","TBX5-Related Holt-Oram Syndrome","Ventriculo-radial syndrome"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301290\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1111\",\"@Source\":\"BookShelf\"}]}}","type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007732\"}","{\"db\":\"OMIM\",\"id\":\"142900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"392\"}","{\"db\":\"OMIM\",\"id\":\"142900\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HOS1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Holt-Oram+syndrome/3457\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"holt-oram-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"19092004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1111\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"142900\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Holt-Oram syndrome"}
{"public_definition":"Branchiootorenal spectrum disorder (BORSD) is characterized by malformations of the outer, middle, and inner ear associated with conductive, sensorineural, or mixed hearing impairment, branchial fistulae and cysts, and renal malformations ranging from mild renal hypoplasia to bilateral renal agenesis. Some individuals progress to end-stage renal disease (ESRD) later in life. Extreme variability can be observed in the presence, severity, and type of branchial arch, otologic, audiologic, and renal abnormality from right side to left side in an affected individual and also among individuals in the same family.","symbol":"BOR1","id":"4708","medgen_id":"C4551702","alternate_symbols":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301554\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1380\",\"@Source\":\"BookShelf\"}]}}","type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007236\"}","{\"db\":\"OMIM\",\"id\":\"113650\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"107\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007236\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"113650\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1380\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"113650\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Branchiootorenal Syndrome 1"}
{"public_definition":"Chorea-acanthocytosis (ChAc) is characterized by a progressive movement disorder, cognitive and behavior changes, a myopathy that can be subclinical, and chronic hyperCKemia in serum. Although the disorder is named for acanthocytosis of the red blood cells, this feature is variable. The movement disorder is mostly limb chorea, but some individuals present with parkinsonism. Dystonia is common and affects the oral region and especially the tongue, causing dysarthria and serious dysphagia with resultant weight loss. Habitual tongue and lip biting are characteristic, as well as tongue protrusion dystonia. Progressive cognitive and behavioral changes resemble those in a frontal lobe syndrome. Seizures are observed in almost half of affected individuals and can be the initial manifestation. Myopathy results in progressive distal muscle wasting and weakness. Mean age of onset in ChAc is about 30 years, although ChAc can develop as early as the first decade or as late as the seventh decade. It runs a chronic progressive course and may lead to major disability within a few years. Life expectancy is reduced, with age of death ranging from 28 to 61 years.","symbol":"CHAC","id":"805","medgen_id":"C0393576","alternate_symbols":[],"alternate_names":["Acanthocytosis with neurologic disorder","Levine-Critchley syndrome"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301561\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1387\",\"@Source\":\"BookShelf\"}]}}","type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008695\"}","{\"db\":\"OMIM\",\"id\":\"200150\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2388\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Choreoacanthocytosis/1384\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1387\",\"ref_field\":\"public_definition\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501217\",\"ref_field\":\"symbol\"}","{\"db\":\"OMIM\",\"id\":\"200150\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Choreoacanthocytosis"}
{"symbol":"CLN2","id":"874","medgen_id":"C1876161","alternate_symbols":[],"alternate_names":["TPP1-Related Neuronal Ceroid-Lipofuscinosis"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301601\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1428\",\"@Source\":\"BookShelf\"}]}}","type":"Disease","gard_id":"3045","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008769\"}","{\"db\":\"OMIM\",\"id\":\"204500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"168491\"}","{\"db\":\"Orphanet\",\"id\":\"228349\"}","{\"db\":\"Orphanet\",\"id\":\"79264\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3045\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"204500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Ceroid lipofuscinosis neuronal 2"}
{"public_definition":"MFN2 hereditary motor and sensory neuropathy (MFN2-HMSN) is a classic axonal peripheral sensorimotor neuropathy, inherited in either an autosomal dominant (AD) manner (~90%) or an autosomal recessive (AR) manner (~10%). MFN2-HMSN is characterized by more severe involvement of the lower extremities than the upper extremities, distal upper-extremity involvement as the neuropathy progresses, more prominent motor deficits than sensory deficits, and normal (\u003e42 m/s) or only slightly decreased nerve conduction velocities (NCVs). Postural tremor is common. Median onset is age 12 years in the AD form and age eight years in the AR form. The prevalence of optic atrophy is approximately 7% in the AD form and approximately 20% in the AR form.","symbol":"HMSN6A","id":"2032","medgen_id":"C0393807","alternate_symbols":["CMT6","CMT6A","HMSN6","HSMN6"],"alternate_names":["CHARCOT-MARIE-TOOTH DISEASE, TYPE 6","CHARCOT-MARIE-TOOTH DISEASE, TYPE 6A","HMSN VIA","NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA","NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA, WITH OPTIC ATROPHY","PERIPHERAL NEUROPATHY AND OPTIC ATROPHY"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301684\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1511\",\"@Source\":\"BookShelf\"}]}}","type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0019551\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, TYPE 6\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, TYPE 6A\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HMSN VIA\"}","{\"db\":\"OMIM\",\"id\":\"608507.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA\"}","{\"db\":\"OMIM\",\"id\":\"608507.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA\"}","{\"db\":\"OMIM\",\"id\":\"608507.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA\"}","{\"db\":\"OMIM\",\"id\":\"608507.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA\"}","{\"db\":\"OMIM\",\"id\":\"608507.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA, WITH OPTIC ATROPHY\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PERIPHERAL NEUROPATHY AND OPTIC ATROPHY\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT6\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT6A\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSN6\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hereditary+motor+and+sensory+neuropathy+with+optic+atrophy/8523\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"128203003\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1511\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Hereditary motor and sensory neuropathy with optic atrophy"}
{"public_definition":"The cerebral creatine deficiency syndromes (CCDS), inborn errors of creatine metabolism, include the two creatine biosynthesis disorders, guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency, and the creatine transporter (CRTR) deficiency. Intellectual disability and seizures are common to all three CCDS. The majority of individuals with GAMT deficiency have a behavior disorder that can include autistic behaviors and self-mutilation; about 40% have movement disorder. Onset is between ages three months and three years. Only 14 individuals with AGAT deficiency have been reported. The phenotype of CRTR deficiency in affected males ranges from mild intellectual disability and speech delay to severe intellectual disability, seizures, movement disorder and behavior disorder; age at diagnosis ranges from two to 66 years. Clinical phenotype of females heterozygous for CRTR deficiency ranges from asymptomatic to severe phenotype resembling male phenotype.","symbol":"CCDS1","id":"1686","medgen_id":"C1845862","alternate_symbols":[],"alternate_names":["CEREBRAL CREATINE DEFICIENCY SYNDROME 1","CREATINE TRANSPORTER DEFECT","Creatine deficiency, X-linked","Mental retardation , X-linked with seizures, short stature and midface hypoplasia","Mental retardation , X-linked, with creatine transport deficiency","SLC6A8-Related Creatine Transporter Deficiency","X-linked creatine deficiency syndrome","X-linked creatine transporter deficiency"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301745\",\"@Source\":\"PubMed\"},{\"$\":\"NBK3794\",\"@Source\":\"BookShelf\"}]}}","type":"Disease","gard_id":"1608","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010305\"}","{\"db\":\"OMIM\",\"id\":\"300352\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"52503\"}","{\"db\":\"OMIM\",\"id\":\"300036.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"300036.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"300036.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"300036.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"300036.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"300036.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"300036.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"300036.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"300036.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"300036.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"300352\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"300352\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CREATINE TRANSPORTER DEFECT\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Creatine+Deficiency%2C+X-Linked/2001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Creatine deficiency, X-linked\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1608\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010305\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK3794\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300352\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Creatine transporter deficiency"}
{"public_definition":"The cerebral creatine deficiency syndromes (CCDS), inborn errors of creatine metabolism, include the two creatine biosynthesis disorders, guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency, and the creatine transporter (CRTR) deficiency. Intellectual disability and seizures are common to all three CCDS. The majority of individuals with GAMT deficiency have a behavior disorder that can include autistic behaviors and self-mutilation; about 40% have movement disorder. Onset is between ages three months and three years. Only 14 individuals with AGAT deficiency have been reported. The phenotype of CRTR deficiency in affected males ranges from mild intellectual disability and speech delay to severe intellectual disability, seizures, movement disorder and behavior disorder; age at diagnosis ranges from two to 66 years. Clinical phenotype of females heterozygous for CRTR deficiency ranges from asymptomatic to severe phenotype resembling male phenotype.","symbol":"L-Arginine","id":"4606","medgen_id":"C2675179","alternate_symbols":["Arginine","CCDS3"],"alternate_names":["AGAT deficiency","CEREBRAL CREATINE DEFICIENCY SYNDROME 3","CREATINE DEFICIENCY SYNDROME DUE TO AGAT DEFICIENCY","GATM DEFICIENCY","L-Arginine:Glycine Amidinotransferase Deficiency"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301745\",\"@Source\":\"PubMed\"},{\"$\":\"NBK3794\",\"@Source\":\"BookShelf\"}]}}","type":"Disease","gard_id":"10323","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012996\"}","{\"db\":\"OMIM\",\"id\":\"612718\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"35704\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0012996\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AGAT deficiency\"}","{\"db\":\"OMIM\",\"id\":\"602360.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 3\"}","{\"db\":\"OMIM\",\"id\":\"602360.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 3\"}","{\"db\":\"OMIM\",\"id\":\"602360.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 3\"}","{\"db\":\"OMIM\",\"id\":\"602360.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 3\"}","{\"db\":\"OMIM\",\"id\":\"602360.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 3\"}","{\"db\":\"OMIM\",\"id\":\"612718\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBRAL CREATINE DEFICIENCY SYNDROME 3\"}","{\"db\":\"OMIM\",\"id\":\"612718\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CREATINE DEFICIENCY SYNDROME DUE TO AGAT DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"612718\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GATM DEFICIENCY\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506385\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"Arginine\"}","{\"db\":\"OMIM\",\"id\":\"612718\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CCDS3\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10323\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"AGAT+Deficiency/261\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK3794\",\"ref_field\":\"public_definition\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000328135\",\"ref_field\":\"symbol\"}"],"name":"Arginine:glycine amidinotransferase deficiency"}
{"public_definition":"Most individuals with classic GBE1 adult polyglucosan body disease (GBE1-APBD) present after age 40 years with unexplained progressive neurogenic bladder, gait difficulties (i.e., spasticity and weakness) from mixed upper and lower motor neuron involvement, sensory loss predominantly in the distal lower extremities, autonomic dysfunction (associated with orthostatic hypotension and constipation), and mild cognitive difficulties (often executive dysfunction). Some affected individuals without classic GBE1-APBD have atypical phenotypes including Alzheimer disease-like dementia and axonal neuropathy, stroke-like episodes, and diaphragmatic failure; others may have a history of infantile liver disease.","symbol":"APBN","id":"3511","medgen_id":"C1849722","alternate_symbols":["APBD"],"alternate_names":["Polyglucosan body disease, adult form"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301758\",\"@Source\":\"PubMed\"},{\"$\":\"NBK5300\",\"@Source\":\"BookShelf\"}]}}","type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009897\"}","{\"db\":\"OMIM\",\"id\":\"263570\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"263570\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"APBD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Polyglucosan+body+disease%2C+adult/5839\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK5300\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"263570\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Polyglucosan body disease, adult"}
{"public_definition":"Crisponi syndrome, the infantile presentation of cold-induced sweating syndrome (CISS), is characterized by dysmorphic features (distinctive facies, lower facial weakness, flexion deformity at the elbows, camptodactyly with fisted hands, misshapen feet, and overriding toes), poor suck reflex and severely impaired swallowing, and temperature spikes associated with an increased risk for seizures and sudden death. During the first decade of life, children with CISS develop profuse sweating of the face, arms, and chest with ambient temperatures below 18 to 22 C, and with other stimuli including apprehension or ingestion of sweets. Affected individuals sweat very little in hot environments and may feel overheated. In the second decade, progressive thoracolumbar kyphoscoliosis requires intervention.","symbol":"CISS1","id":"981","medgen_id":"C1848947","alternate_symbols":[],"alternate_names":["CRISPONI/COLD-INDUCED SWEATING SYNDROME 1","Crisponi syndrome","Muscle contractions, tetanoform, with characteristic face, camptodactyly, hyperthermia, and sudden death"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"21370513\",\"@Source\":\"PubMed\"},{\"$\":\"NBK52917\",\"@Source\":\"BookShelf\"}]}}","type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010091\"}","{\"db\":\"OMIM\",\"id\":\"272430\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1545\"}","{\"db\":\"Orphanet\",\"id\":\"157820\"}","{\"db\":\"OMIM\",\"id\":\"272430\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CRISPONI/COLD-INDUCED SWEATING SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"604237.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CRISPONI/COLD-INDUCED SWEATING SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"604237.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CRISPONI/COLD-INDUCED SWEATING SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"604237.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CRISPONI/COLD-INDUCED SWEATING SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"604237.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CRISPONI/COLD-INDUCED SWEATING SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"604237.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CRISPONI/COLD-INDUCED SWEATING SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"604237.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CRISPONI/COLD-INDUCED SWEATING SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"604237.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CRISPONI/COLD-INDUCED SWEATING SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"604237.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CRISPONI/COLD-INDUCED SWEATING SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"604237.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CRISPONI/COLD-INDUCED SWEATING SYNDROME 1\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010091\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Crisponi syndrome\"}","{\"db\":\"Orphanet\",\"id\":\"1545\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Crisponi syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cold-induced+sweating+syndrome+1/8000\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Crisponi+Syndrome/2012\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK52917\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"272430\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Cold-induced sweating syndrome 1"}
{"public_definition":"The clinical manifestations of glycogen storage disease type IV (GSD IV) discussed in this entry span a continuum of different subtypes with variable ages of onset, severity, and clinical features. Clinical findings vary extensively both within and between families. The fatal perinatal neuromuscular subtype presents in utero with fetal akinesia deformation sequence, including decreased fetal movements, polyhydramnios, and fetal hydrops. Death usually occurs in the neonatal period. The congenital neuromuscular subtype presents in the newborn period with profound hypotonia, respiratory distress, and dilated cardiomyopathy. Death usually occurs in early infancy. Infants with the classic (progressive) hepatic subtype may appear normal at birth, but rapidly develop failure to thrive; hepatomegaly, liver dysfunction, and progressive liver cirrhosis; hypotonia; and cardiomyopathy. Without liver transplantation, death from liver failure usually occurs by age five years. Children with the non-progressive hepatic subtype tend to present with hepatomegaly, liver dysfunction, myopathy, and hypotonia; however, they are likely to survive without progression of the liver disease and may not show cardiac, skeletal muscle, or neurologic involvement. The childhood neuromuscular subtype is rare and the course is variable, ranging from onset in the second decade with a mild disease course to a more severe, progressive course resulting in death in the third decade.","symbol":"GSD4","id":"5200","medgen_id":"C0017923","alternate_symbols":[],"alternate_names":["Amylopectinosis","Andersen disease","Brancher deficiency","Cirrhosis, familial, with deposition of abnormal glycogen","GBE1 DEFICIENCY","GLYCOGENOSIS IV","GSD 4","GSD IV","Glycogen branching enzyme deficiency","Glycogen storage disease type 4","Glycogenosis 4"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23285490\",\"@Source\":\"PubMed\"},{\"$\":\"NBK115333\",\"@Source\":\"BookShelf\"}]}}","type":"Disease","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009292\"}","{\"db\":\"OMIM\",\"id\":\"232500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"367\"}","{\"db\":\"OMIM\",\"id\":\"232500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GBE1 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"232500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GLYCOGENOSIS IV\"}","{\"db\":\"OMIM\",\"id\":\"232500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GSD IV\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Glycogen+Storage+Disease+Type+4/3124\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"11179002\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK115333\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"232500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Glycogen storage disease, type IV"}
{"public_definition":"The 17q12 recurrent deletion syndrome is characterized by variable combinations of the three following findings: structural or functional abnormalities of the kidney and urinary tract, maturity-onset diabetes of the young type 5 (MODY5), and neurodevelopmental or neuropsychiatric disorders (e.g., developmental delay, intellectual disability, autism spectrum disorder, schizophrenia, anxiety, and bipolar disorder). Using a method of data analysis that avoids ascertainment bias, the authors determined that multicystic kidneys and other structural and functional kidney anomalies occur in 85% to 90% of affected individuals, MODY5 in approximately 40%, and some degree of developmental delay or learning disability in approximately 50%. MODY5 is most often diagnosed before age 25 years (range: age 10-50 years).","id":"16859","medgen_id":"C3281138","alternate_symbols":[],"alternate_names":["17q12 Microdeletion Syndrome","17q12 Recurrent Microdeletion Syndrome"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27929632\",\"@Source\":\"PubMed\"},{\"$\":\"NBK401562\",\"@Source\":\"BookShelf\"}]}}","type":"Disease","gard_id":"13297","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013797\"}","{\"db\":\"OMIM\",\"id\":\"614527\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"261265\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"13297\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK401562\",\"ref_field\":\"public_definition\"}"],"name":"Chromosome 17q12 deletion syndrome"}
{"public_definition":"Tangier disease is characterized by severe deficiency or absence of high-density lipoprotein (HDL) in the circulation resulting in tissue accumulation of cholesteryl esters throughout the body, particularly in the reticuloendothelial system. The major clinical signs of Tangier disease include hyperplastic yellow-orange tonsils, hepatosplenomegaly, and peripheral neuropathy, which may be either relapsing-remitting or chronic progressive in nature. Rarer complications may include corneal opacities that typically do not affect vision, premature atherosclerotic coronary artery disease occurring in the sixth and seventh decades of life (not usually before age 40 years), and mild hematologic manifestations, such as mild thrombocytopenia, reticulocytosis, stomatocytosis, or hemolytic anemia. The clinical expression of Tangier disease is variable, with some affected individuals only showing biochemical perturbations.","symbol":"TGD","id":"6024","medgen_id":"C0039292","alternate_symbols":["HDLDT1"],"alternate_names":["A-alphalipoprotein neuropathy","Alpha high density lipoprotein deficiency disease","Analphalipo-proteinemia","Cholesterol thesaurismosis","Familial Hypoalphalipo-proteinemia","Familial high density lipoprotein deficiency disease","Hdl lipoprotein deficiency disease","High density lipoprotein deficiency, Tangier type","High density lipoprotein deficiency, type 1"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31751110\",\"@Source\":\"PubMed\"},{\"$\":\"NBK549920\",\"@Source\":\"BookShelf\"}]}}","type":"Disease","gard_id":"7731","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008783\"}","{\"db\":\"OMIM\",\"id\":\"205400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"31150\"}","{\"db\":\"OMIM\",\"id\":\"205400\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HDLDT1\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7731\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Tangier+disease/6997\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"tangier-disease\",\"ref_field\":\"name\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008783\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK549920\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"205400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Tangier disease"}
{"public_definition":"The hereditary ataxias are a group of genetic disorders characterized by slowly progressive incoordination of gait and often associated with poor coordination of hands, speech, and eye movements. Frequently, atrophy of the cerebellum occurs. In this GeneReview the hereditary ataxias are categorized by mode of inheritance and gene (or chromosome locus) in which pathogenic variants occur.","symbol":"SCA29","id":"4436","medgen_id":"C1861732","alternate_symbols":["ACV","CNPCA"],"alternate_names":["CEREBELLAR ATAXIA, CONGENITAL NONPROGRESSIVE, AUTOSOMAL DOMINANT","Cerebellar ataxia early-onset nonprogressive"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301317\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1138\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20050888\",\"@Source\":\"PubMed\"}}]}","type":"Disease","gard_id":"10480","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007298\"}","{\"db\":\"OMIM\",\"id\":\"117360\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"208513\"}","{\"db\":\"OMIM\",\"id\":\"117360\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBELLAR ATAXIA, CONGENITAL NONPROGRESSIVE, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"117360\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ACV\"}","{\"db\":\"OMIM\",\"id\":\"117360\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CNPCA\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10480\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007298\",\"ref_field\":\"name\"}","{\"db\":\"NCBI for submitter\",\"id\":\"genomeconnect_17475_622\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1138\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"117360\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Spinocerebellar ataxia type 29"}
{"symbol":"THPH1","id":"24727","medgen_id":"C3160733","alternate_symbols":["F2"],"alternate_names":["Prothrombin-Related Thrombophilia (Factor II)","THROMBOPHILIA DUE TO FACTOR 2 DEFECT","Thrombosis susceptibility"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301327\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1148\",\"@Source\":\"BookShelf\"}]}}","disease_mechanism_id":"274","type":"Finding","gard_id":"10815","disease_mechanism":"gain of function","keywords":[],"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000323271\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000525921\"}]}"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008559\"}","{\"db\":\"OMIM\",\"id\":\"188050\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"188050\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THROMBOPHILIA DUE TO FACTOR 2 DEFECT\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500305\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"F2\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000025288\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000174333\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000321099\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331922\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331933\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332126\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502122\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502510\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000503192\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507481\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509249\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511144\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520021\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520078\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521336\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521660\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530629\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000531243\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552060\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556387\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10815\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008559\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"188050\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Thrombophilia due to thrombin defect"}
{"public_definition":"Thanatophoric dysplasia (TD) is a short-limb skeletal dysplasia that is usually lethal in the perinatal period. TD is divided into subtypes: TD type I is characterized by micromelia with bowed femurs and, uncommonly, the presence of craniosynostosis of varying severity. TD type II is characterized by micromelia with straight femurs and uniform presence of moderate-to-severe craniosynostosis with cloverleaf skull deformity. Other features common to type I and type II include: short ribs, narrow thorax, relative macrocephaly, distinctive facial features, brachydactyly, hypotonia, and redundant skin folds along the limbs. Most affected infants die of respiratory insufficiency shortly after birth. Rare long-term survivors have been reported.","symbol":"TD1","id":"4254","medgen_id":"C1868678","alternate_symbols":[],"alternate_names":["LETHAL SHORT-LIMBED PLATYSPONDYLIC DWARFISM, SAN DIEGO TYPE","PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, SAN DIEGO TYPE"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301540\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1366\",\"@Source\":\"BookShelf\"}]}}","disease_mechanism_id":"274","type":"Disease","disease_mechanism":"gain of function","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008546\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1860\"}","{\"db\":\"Orphanet\",\"id\":\"2655\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LETHAL SHORT-LIMBED PLATYSPONDYLIC DWARFISM, SAN DIEGO TYPE\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, SAN DIEGO TYPE\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000226129\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320916\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000327813\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508854\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508990\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512698\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514902\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518899\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522271\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530324\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568358\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Thanatophoric+dysplasia+type+1/7051\",\"ref_field\":\"name\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008546\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1366\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Thanatophoric dysplasia type 1"}
{"public_definition":"Factor V Leiden thrombophilia is characterized by a poor anticoagulant response to activated protein C (APC) and an increased risk for venous thromboembolism (VTE). Deep vein thrombosis (DVT) is the most common VTE, with the legs being the most common site. Thrombosis in unusual locations is less common. Evidence suggests that heterozygosity for the Leiden variant has at most a modest effect on risk for recurrent thrombosis after initial treatment of a first VTE. It is unlikely that factor V Leiden thrombophilia (i.e., heterozygosity or homozygosity for the Leiden variant) is a major factor contributing to pregnancy loss and other adverse pregnancy outcomes (preeclampsia, fetal growth restriction, and placental abruption). The clinical expression of factor V Leiden thrombophilia is influenced by the following: The number of Leiden variants (heterozygotes have a slightly increased risk for venous thrombosis; homozygotes have a much greater thrombotic risk). Coexisting genetic thrombophilic disorders, which have a supra-additive effect on overall thrombotic risk. Acquired thrombophilic disorders: antiphospholipid antibody (APLA) syndrome, paroxysmal nocturnal hemoglobinuria, myeloproliferative disorders, and increased levels of clotting factors. Circumstantial risk factors including but not limited to pregnancy, central venous catheters, travel, combined oral contraceptive (COC) use and other combined contraceptives, oral hormone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), obesity, leg injury, and advancing age.","symbol":"THPH2","id":"4548","medgen_id":"C1861171","alternate_symbols":["5FLE","THPH1"],"alternate_names":["ACTIVATED PROTEIN C RESISTANCE","APC RESISTANCE","PCCF DEFICIENCY","PROC COFACTOR DEFICIENCY","THROMBOPHILIA DUE TO DEFICIENCY OF ACTIVATED PROTEIN C COFACTOR","THROMBOPHILIA V"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301542\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1368\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACOG, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20027064\",\"@Source\":\"PubMed\"}}]}","disease_mechanism_id":"274","type":"Disease","disease_mechanism":"gain of function","keywords":[],"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000174331\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000320550\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000502535\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000332439\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000521336\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000509324\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000562501\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000531243\"}]}"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008560\"}","{\"db\":\"OMIM\",\"id\":\"188055\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"188055\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ACTIVATED PROTEIN C RESISTANCE\"}","{\"db\":\"OMIM\",\"id\":\"188055\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"APC RESISTANCE\"}","{\"db\":\"OMIM\",\"id\":\"188055\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PCCF DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"188055\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PROC COFACTOR DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"188055\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THROMBOPHILIA DUE TO DEFICIENCY OF ACTIVATED PROTEIN C COFACTOR\"}","{\"db\":\"OMIM\",\"id\":\"188055\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THROMBOPHILIA V\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000024913\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"5FLE\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000325434\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Thrombophilia+due+to+activated+protein+C+resistance/9393\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1368\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"188055\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Thrombophilia due to activated protein C resistance"}
{"public_definition":"Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, stomach, ovary, small bowel, hepatobiliary tract, urinary tract, brain, and skin. In individuals with Lynch syndrome the following lifetime risks for cancer are seen: CRC: 52%-82% (mean age at diagnosis 44-61 years). Endometrial cancer in females: 25%-60% (mean age at diagnosis 48-62 years). Gastric cancer: 6%-13% (mean age at diagnosis 56 years). Ovarian cancer: 4%-12% (mean age at diagnosis 42.5 years; ~30% are diagnosed \u003c age 40 years). The risk for other Lynch syndrome-related cancers is lower, though substantially increased over general population rates.","symbol":"MMRCS1","id":"3207","medgen_id":"C0265325","alternate_symbols":["BTPS1","CMMRDS","MSH2","MSH6"],"alternate_names":["BRAIN TUMOR-POLYPOSIS SYNDROME 1","BTP1 SYNDROME","CHILDHOOD CANCER SYNDROME","CNS tumors with Familial polyposis of the colon","Constitutional mismatch repair deficiency syndrome","MISMATCH REPAIR CANCER SYNDROME 1","MISMATCH REPAIR DEFICIENCY","MLH1-Related Hereditary Non-Polyposis Colon Cancer","MLH1-Related Turcot Syndrome","MMR DEFICIENCY","MSH2-Related Turcot Syndrome","MSH6-Related Hereditary Non-Polyposis Colon Cancer","MSH6-Related Turcot Syndrome","Malignant tumors of the central nervous system associated with familial polyposis of the colon","PMS2-Related Hereditary Non-Polyposis Colon Cancer","PMS2-Related Lynch Syndrome","PMS2-Related Turcot Syndrome"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301390\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1211\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"NSGC, 2004\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"15604628\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG/NSGC, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25394175\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO/ESMO, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25452455\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC/CCA-ICC, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22167527\",\"@Source\":\"PubMed\"}}]}","disease_mechanism_id":"273","type":"Disease","gard_id":"420","disease_mechanism":"loss of function","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010159\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"252202\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BRAIN TUMOR-POLYPOSIS SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BTP1 SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHILDHOOD CANCER SYNDROME\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010159\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Constitutional mismatch repair deficiency syndrome\"}","{\"db\":\"Orphanet\",\"id\":\"252202\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Constitutional mismatch repair deficiency syndrome\"}","{\"db\":\"OMIM\",\"id\":\"120436.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"120436.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"120436.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"120436.0020\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"120436.0027\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"120436.0028\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"120436.0034\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR CANCER SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MISMATCH REPAIR DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MMR DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BTPS1\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMMRDS\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000317455\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MSH2\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000317455\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000317457\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000328927\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501396\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501398\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501399\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501400\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501401\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501402\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501424\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501797\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515534\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515899\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518997\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520069\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527981\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527982\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527984\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528519\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528912\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528914\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528915\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528930\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529017\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530120\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530202\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569423\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"420\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Turcot+syndrome/7267\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"61665008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1211\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"276300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Turcot syndrome"}
{"public_definition":"Refsum disease is characterized by anosmia and early-onset retinitis pigmentosa, which are both universal findings with variable combinations of neuropathy, deafness, ataxia, and ichthyosis. Onset of symptoms ranges from age seven months to older than age 50 years. Cardiac arrhythmia and heart failure caused by cardiomyopathy are potentially severe health problems that develop later in life.","symbol":"RDPA","id":"5851","medgen_id":"C0034960","alternate_symbols":["HMSN4"],"alternate_names":["Disorder of cornification 11 (phytanic acid type)","Doc 11 (phytanic acid type)","HMSN 4","HMSN IV","Herditary sensory and motor neuropathy type 4","Heredopathia atactica polyneuritiformis","Hypertrophic neuropathy of Refsum","Phytanic acid oxidase deficiency","REFSUM DISEASE, CLASSIC"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301527\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1353\",\"@Source\":\"BookShelf\"}]}}","disease_mechanism_id":"273","type":"Disease","disease_mechanism":"loss of function","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009958\"}","{\"db\":\"OMIM\",\"id\":\"266500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"773\"}","{\"db\":\"OMIM\",\"id\":\"266500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HMSN IV\"}","{\"db\":\"OMIM\",\"id\":\"266500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"REFSUM DISEASE, CLASSIC\"}","{\"db\":\"OMIM\",\"id\":\"266500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSN4\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000004880\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000318975\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506571\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506572\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515436\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525961\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553865\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561876\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569521\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Phytanic+acid+storage+disease/9107\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Refsum+disease+with+increased+pipecolic+acidemia/6182\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"25362006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1353\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"600964\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Phytanic acid storage disease"}
{"public_definition":"The term \"galactosemia\" refers to disorders of galactose metabolism that include classic galactosemia, clinical variant galactosemia, and biochemical variant galactosemia. This GeneReview focuses on: Classic galactosemia, which can result in life-threatening complications including feeding problems, failure to thrive, hepatocellular damage, bleeding, and E coli sepsis in untreated infants. If a lactose-restricted diet is provided during the first ten days of life, the neonatal signs usually quickly resolve and the complications of liver failure, sepsis, and neonatal death are prevented; however, despite adequate treatment from an early age, children with classic galactosemia remain at increased risk for developmental delays, speech problems (termed childhood apraxia of speech and dysarthria), and abnormalities of motor function. Almost all females with classic galactosemia manifest premature ovarian insufficiency (POI). Clinical variant galactosemia, which can result in life-threatening complications including feeding problems, failure to thrive, hepatocellular damage including cirrhosis, and bleeding in untreated infants. This is exemplified by the disease that occurs in African Americans and native Africans in South Africa. Persons with clinical variant galactosemia may be missed with newborn screening (NBS) as the hypergalactosemia is not as marked as in classic galactosemia and breath testing is normal. If a lactose-restricted diet is provided during the first ten days of life, the severe acute neonatal complications are usually prevented. African Americans with clinical variant galactosemia and adequate early treatment do not appear to be at risk for long-term complications including POI.","id":"16954","medgen_id":"C0016952","alternate_symbols":[],"alternate_names":["Galactose intolerance"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301691\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1518\",\"@Source\":\"BookShelf\"}]}}","disease_mechanism_id":"273","type":"Disease","gard_id":"2424","disease_mechanism":"loss of function","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004919\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0018116\"}","{\"db\":\"Orphanet\",\"id\":\"352\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004919\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Galactose intolerance\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569081\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591986\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2424\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Galactosemia/2973\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"190745006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1518\",\"ref_field\":\"public_definition\"}"],"name":"Galactosemia"}
{"public_definition":"Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability, severe speech impairment, gait ataxia and/or tremulousness of the limbs, and a unique behavior with an inappropriate happy demeanor that includes frequent laughing, smiling, and excitability. Microcephaly and seizures are also common. Developmental delays are first noted at around age six months; however, the unique clinical features of AS do not become manifest until after age one year, and it can take several years before the correct clinical diagnosis is obvious.","symbol":"AS","id":"404","medgen_id":"C0162635","alternate_symbols":[],"alternate_names":["HAPPY PUPPET SYNDROME","Happy puppet syndrome (formerly)"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301323\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1144\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111049\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"Eurogentest, 2008\",\"@Type\":\"Translational/Evidence-based\",\"URL\":{\"$\":\"http://www.eurogentest.org/web/files/public/unit3/ClinicalUtilityGeneCards/Indication%20criteria%20-%20AS.pdf\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23519317\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESHG/ASHG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25782669\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"27467454\",\"@Source\":\"PubMed\"}}]}","disease_mechanism_id":"273","type":"Disease","gard_id":"5810","disease_mechanism":"loss of function","mode_of_inheritance":"AS is caused by disruption of maternally imprinted UBE3A located within the 15q11.2-q13 Angelman syndrome/Prader-Willi syndrome (AS/PWS) region.","keywords":[],"attribute_content":["{\"Attribute\":{\"$\":\"imprinting disorder\",\"@Type\":\"mode of inheritance\"},\"XRef\":{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260593\"}}"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007113\"}","{\"db\":\"OMIM\",\"id\":\"105830\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"72\"}","{\"db\":\"OMIM\",\"id\":\"105830\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HAPPY PUPPET SYNDROME\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000226643\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260593\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331374\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000503131\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507771\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508896\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508937\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509438\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519582\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520979\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520995\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520996\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520998\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521642\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522320\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525860\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525867\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527540\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529013\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530102\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530118\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000531722\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551668\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552178\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552326\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552341\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556577\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556612\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558215\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558216\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558805\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558906\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568029\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568371\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5810\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501320\",\"ref_field\":\"mode_of_inheritance\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Angelman+Syndrome/452\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"angelman-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"76880004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1144\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"105830\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Angelman syndrome"}
{"public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (a-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% a-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% a-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.","id":"1790","medgen_id":"C0002986","alternate_symbols":[],"alternate_names":["Alpha-galactosidase A deficiency","Anderson-Fabry disease","Angiokeratoma corporis diffusum","Angiokeratoma, diffuse","Ceramide trihexosidase deficiency","Ceramide trihexosidosis","Fabry syndrome","Fabry's disease","GLA deficiency","Hereditary dystopic lipidosis"],"content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","type":"Disease","gard_id":"6400","disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.","keywords":[],"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000591289\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"}]}"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010526\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"name":"Fabry disease"}
